CA3230072A1 - Human monocarboxylate transporter 1 antibodies and uses thereof - Google Patents

Human monocarboxylate transporter 1 antibodies and uses thereof Download PDF

Info

Publication number
CA3230072A1
CA3230072A1 CA3230072A CA3230072A CA3230072A1 CA 3230072 A1 CA3230072 A1 CA 3230072A1 CA 3230072 A CA3230072 A CA 3230072A CA 3230072 A CA3230072 A CA 3230072A CA 3230072 A1 CA3230072 A1 CA 3230072A1
Authority
CA
Canada
Prior art keywords
seq
antibody
comprises seq
nucleic acid
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3230072A
Other languages
English (en)
French (fr)
Inventor
Frank Charles DORSEY
Joseph Benjamin GRANGER
Kira Vladimirovna RUBTSOVA
Oliver SCHROEDER
Wei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunometabolism Development Company LLC
Original Assignee
Immunometabolism Development Company LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunometabolism Development Company LLC filed Critical Immunometabolism Development Company LLC
Publication of CA3230072A1 publication Critical patent/CA3230072A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3230072A 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof Pending CA3230072A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US63/261,177 2021-09-14
US202163272903P 2021-10-28 2021-10-28
US63/272,903 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3230072A1 true CA3230072A1 (en) 2023-03-23

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3230072A Pending CA3230072A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
CA3087259A1 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Also Published As

Publication number Publication date
TWI842088B (zh) 2024-05-11
KR20240053656A (ko) 2024-04-24
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
JP7753348B2 (ja) 2025-10-14
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
DOP2024000049A (es) 2024-06-16
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JOP20240054A1 (ar) 2024-03-13
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20240141042A1 (en) MULTISPECIFIC NKp46 BINDING PROTEINS
JP6976241B2 (ja) 抗ｔｉｇｉｔ抗体
US12304957B2 (en) Anti-CD161 antibodies and uses thereof
EP4214240B1 (en) Anti-ccr8 antibodies
AU2019356806A1 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP2026004435A (ja) ヒトモノカルボン酸トランスポーター１抗体及びその使用
CA3169155C (en) Anti-human cd19 antibodies
CN118043353A (zh) 人单羧酸转运蛋白1抗体及其用途
CA3220353A1 (en) Use of anti-ctla-4 antibody
HK40099253A (en) Use of anti-ctla-4 antibody
HK40099253B (en) Use of anti-ctla-4 antibody
HK40120864A (zh) 抗ctla-4抗体的用途
HK40100657B (en) Anti-ccr8 antibodies
HK40100657A (en) Anti-ccr8 antibodies
CA3169155A1 (en) Anti-human cd19 antibodies
EA040943B1 (ru) Антитела к cd154 и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240415

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251001

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260204